Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Both hybrid and high-dose dual therapies developed by the scholars from Taiwan can achieve a
high eradication rate for clarithromycin-resistant strains, and have a great potential to
replace bismuth quadruple therapy in the treatment of H. pylori infection.